. 2017 Nov 28;7(1):115–123. doi: 10.1530/EC-17-0327
This work is licensed under a Table 1.
Effect of 26 weeks of treatment with liraglutide or place in a PCOS cohort.
| Liraglutide baseline | Change at follow-up | Placebo baseline | Change at follow-up | Difference between groups | P-Value | |
|---|---|---|---|---|---|---|
| Weight (kg) | 94.2 ± 15.4 | −5.2 ± 0.7 | 91.3 ± 13.6 | 0.2 ± 0.9 | −5.2 (−7.5 to −3.0) | <0.001 |
| BMI (kg/m2) | 33.3 ± 5.1 | −1.9 ± 0.3 | 33.3 ± 4.6 | 0.1 ± 0.3 | −1.8 (−2.7 to −1.0) | <0.001 |
| Waist (cm) | 102.6 ± 10.8 | −4.1 ± 1.1 | 102.6 ± 11.1 | 1.1 ± 1.5 | −5.7 (−9.3 to −1.9) | 0.01 |
| Systolic BP (mmHg) | 123 ± 9 | −3 ± 1 | 124 ± 9 | −2 ± 2 | −1.6 (−4.8 to 2.5) | 0.53 |
| Diastolic BP (mmHg) | 79 ± 8 | −1 ± 1 | 80 ± 7 | −1 ± 1 | −0.04 (−2.9 to 2.8) | 0.35 |
| Heart rate (bmp) | 76 ± 9 | 6 ± 1 | 79 ± 15 | −1 ± 2 | 6.4 (2.4–10.4) | 0.006 |
| Total cholesterol | 4.61 ± 0.80 | 0.03 ± 0.09 | 4.67 ± 0.57 | 0.08 ± 0.09 | −0.01 (−0.10 to 0.07) | 0.35 |
| LDL cholesterol | 2.83 ± 0.71 | 0.14 ± 0.09 | 2.99 ± 0.54 | 0.13 ± 0.09 | −0.01 (−0.29 to 0.26) | 0.92 |
| HDL cholesterol | 1.14 ± 0.25 | −0.01 ± 0.02 | 1.09 ± 0.28 | 0.01 ± 0.03 | −0.01 (−0.09 to 0.06) | 0.77 |
| Triglycerides | 1.23 (0.90–1.63) | −0.22 (−0.36 to −0.09) | 1.15 (0.90–1.47) | −0.11 (−0.37 to 0.14) | 0.94 (0.82–1.07) | 0.32 |
| HbA1C (mmol/mol) | 34.2 ± 2.8 | −1.3 ± 0.4 | 34.6 ± 3.4 | 0.1 ± 0.5 | −1.38 (−2.48 to −0.28) | 0.015 |
| HOMA2-IR | 2.29 (1.83–2.84) | −0.27 ± 0.15 | 2.42 (1.91–3.20) | −0.28 ± 0.20 | Ratio 0.93 (0.75–1.01) | 0.48 |
| Matsuda index | 2.13 (1.47–2.81) | 0.41 ± 0.19 | 2.04 (1.21–2.70) | 0.34 ± 0.24 | Ratio 1.08 (0.96–1.34) | 0.49 |
| eGFR (mL/min/1.73 m2) | 113 ± 13 | 1 ± 1 | 118 ± 10 | −2 ± 1 | 2 (−3 to 5) | 0.48 |
| DXA fat mass (kg) | 35.9 ± 8.5 | −2.6 ± 0.5 | 35.7 ± 7.2 | 0.3 ± 0.7 | −2.8 (−4.6 to 1.1) | 0.002 |
| DXA lean mass (kg) | 58.8 ± 8.0 | −2.4 ± 0.4 | 56.0 ± 7.0 | 0.1 ± 0.4 | −2.3 (−3.5 to −1.2) | <0.001 |
| MRI VAT (cm3) | 115.7 ± 51.4 (n = 44) | −17.2 ± 4.3 (n = 37) | 120.9 ± 42.3 (n = 23) | 4.50 ± 7.0 (n = 20) | −21.9 (−37.3 to −6.5) | 0.006 |
| MRI SAT (cm3) | 407.4 ± 121.4 (n = 44) | −40.1 ± 10.5 (n = 37) | 409.6 ± 125.3 (n = 23) | −0.35 ± 9.94 (n = 20) | −40.7 (−72.3 to −9.1) | 0.013 |
| MR-proADM (nmol/L) | 0.52 (0.45–0.56) | −0.02 (−0.04 to 0.002) | 0.55 (0.49–0.62) | 0.003 (−0.018 to 0.024) | Ratio 0.94 (0.89–1.002) | 0.057 |
| Copeptin (pmol/L) | 4.95 (3.50–6.50) | 0.48 (−0.39 to 1.34) | 5.30 (3.90–7.40) | 0.28 (−0.51 to 1.08) | Ratio 1.04 (0.87–1.25) | 0.64 |
| MR-proANP (pmol/L) | 44.8 (34.6–56.7) | −11.5 (−17.0 to −6.1) | 48.1 (32.1–56.0) | 1.4 (−7.5 to 10.2) | Ratio 0.75 (0.63–0.89) | 0.001 |
Baseline values, changes at 26 weeks follow, and between-group difference after treatment. Mean ± s.d., median (interquartile range), (95% CI).
MR-proADM, midregional proadrenomedullin; MR-proANP, midregional proatrial natriuretic peptide; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.